- Jupiter Wellness Inc JUPW has signed an exclusive licensing agreement with Rejoy Inc to develop prescription products for the treatment of nipple neuropathies for breast cancer patients.
- The exclusive license includes issued patents and technology, including formulations.
- Related: Jupiter Wellness Registers 400% Jump In Q2 Revenue
- In clinical studies, one topical formulation improved nipple sensitivity and alleviated associated sexual problems.
- The product has been named JW-500 to be added to a line of other clinical stage products currently under development.
- Jupiter Wellness plans to file for a pre-IND meeting with the FDA within the next 12 months and intends to seek Orphan Drug Designation.
- Price Action: JUPW shares are trading higher by 1.63% at $1.05 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
